Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSerco Regulatory News (SRP)

Share Price Information for Serco (SRP)

Share Price is delayed by 15 minutes
Get Live Data
255.80    1.40 (0.55%)
Bid:
254.00
Ask:
254.60
Spread: 0.60 (0.236%)
Market Cap: £2.51b
SRP Live PriceLast checked at - London Stock Exchange

Intraday Serco Share Chart

Serco wins CMS rebid valued at $690m

23 Feb 2023 07:00

RNS Number : 7715Q
Serco Group PLC
23 February 2023
 

Serco wins CMS rebid valued at $690m

 

23 February 2023

 

Serco has been awarded a contract by the US Department of Health and Human Services, Centers for Medicare & Medicaid Services (CMS) to continue to support eligibility determinations for citizens purchasing health insurance through the Federal Health Insurance Exchanges. The 4 year and 7-month contract has a one-year base period and four option periods, and is due to start on 1 July 2023. The estimated total value to Serco, subject to workload volumes, is approximately $690 million if all option periods are exercised.

 

CMS serves the public as a trusted partner and steward, dedicated to advancing health equity, expanding coverage, and improving health outcomes, and now oversees the health coverage of more than 150 million people.

 

Serco will assist qualified citizens to receive health insurance through the Affordable Care Act by taking a unified approach to operational services, customer support, data analytics, and program management, all aimed at continuously optimising service delivery and program integrity.

 

Mark Irwin, Serco Group Chief Executive, said: 'We are grateful for the trust CMS has placed in us to continue to deliver these vital eligibility services building on the value-based relationship we have formed since commencing these services in 2013. During this time, we have assisted tens of millions of Americans on their health journey, and as an impact partner to CMS, we are fully committed to continuous improvement in citizen experience and delivering our case management expertise in support of the strategic goals of our customer.'

 

 

 

This announcement contains inside information.

 

Ends

 

For further information please contact:

Paul Checketts, Head of Investor Relations, tel: +44 (0) 7718 195 074 or email: paul.checketts@serco.com

Marcus De Ville, Head of Media Relations; tel +44 (0) 7738 898 550 or email: marcus.deville@serco.com

 

About Serco

Serco is a leading provider of public services. Our customers are governments or others operating in the public sector. We gain scale, expertise and diversification by operating internationally across five sectors and four geographies: Defence, Justice & Immigration, Transport, Health and Citizen Services, delivered in UK & Europe, North America, Asia Pacific and the Middle East.

 

More information can be found at www.serco.com

 

 

Forward looking statements

This announcement contains statements which are, or may be deemed to be, "forward-looking statements" which are prospective in nature. All statements other than statements of historical fact are forward-looking statements. Generally, words such as "expect", "anticipate", "may", "could", "should", "will", "aspire", "aim", "plan", "target", "goal", "ambition", "intend" and similar expressions identify forward looking-statements. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Factors which may cause future outcomes to differ from those foreseen or implied in forward-looking statements include, but are not limited to: general economic conditions and business conditions in Serco's markets; contracts awarded to Serco; customers' acceptance of Serco's products and services; operational problems; the actions of competitors, trading partners, creditors, rating agencies and others; the success or otherwise of partnering; changes in laws and governmental regulations; regulatory or legal actions, including the types of enforcement action pursued and the nature of remedies sought or imposed; the receipt of relevant third party and/or regulatory approvals; exchange rate fluctuations; the development and use of new technology; changes in public expectations and other changes to business conditions; wars and acts of terrorism; cyber-attacks; and pandemics, epidemics or natural disasters. Many of these factors are beyond Serco's control or influence. These forward-looking statements speak only as of the date of this announcement and have not been audited or otherwise independently verified. Past performance should not be taken as an indication or guarantee of future results and no representation or warranty, express or implied, is made regarding future performance. Except as required by any applicable law or regulation, Serco expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained in this announcement to reflect any change in Serco's expectations or any change in events, conditions or circumstances on which any such statement is based after the date of this announcement, or to keep current any other information contained in this announcement. Accordingly, undue reliance should not be placed on the forward-looking statements.

 

LEI: 549300PT2CIHYN5GWJ21

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUUURROSUUUUR
Date   Source Headline
5th Jun 20265:36 pmRNSTransaction in Own Shares
29th May 20265:35 pmRNSTransaction in Own Shares and Total Voting Rights
26th May 20267:00 amRNSSerco secures £270m contract from NNUH
22nd May 20265:14 pmRNSTransaction in Own Shares
15th May 20265:24 pmRNSTransaction in Own Shares
8th May 20265:25 pmRNSTransaction in Own Shares
30th Apr 20265:37 pmRNSTransactions in own shares and Total Voting Rights
24th Apr 20265:17 pmRNSTransactions in Own Shares
22nd Apr 20264:00 pmRNSResult of AGM
17th Apr 20265:34 pmRNSTransactions in Own Shares
10th Apr 20265:39 pmRNSTransactions in Own Shares
10th Apr 20263:46 pmRNSDirector/PDMR Shareholding
7th Apr 20265:35 pmRNSDirector/PDMR Shareholding
31st Mar 20265:21 pmRNSTransactions in Own Shares and Total Voting Rights
27th Mar 20263:03 pmRNSDirector/PDMR Shareholding
20th Mar 20265:50 pmRNSTransaction in Own Shares
18th Mar 20265:15 pmRNSHolding(s) in Company
18th Mar 202611:00 amRNSPublication of the 2025 ARA and 2026 Notice of AGM
13th Mar 20265:25 pmRNSTransaction in Own Shares
11th Mar 20265:46 pmRNSTransaction in Own Shares and Total Voting Rights
5th Mar 20267:02 amRNSShare Repurchase Programme
5th Mar 20267:00 amRNS2025 full year results
19th Feb 20265:45 pmRNSHolding(s) in Company
9th Feb 20265:30 pmRNSHolding(s) in Company
5th Feb 202612:30 pmRNSHolding(s) in Company
2nd Feb 20265:45 pmRNSTotal Voting Rights and Capital
29th Jan 20265:30 pmRNSHolding(s) in Company
5th Jan 20265:30 pmRNSHolding(s) in Company
31st Dec 20259:00 amRNSTotal Voting Rights and Capital
31st Dec 20259:00 amRNSTotal Voting Rights and Capital
23rd Dec 20254:00 pmRNSHolding(s) in Company
23rd Dec 20254:00 pmRNSHolding(s) in Company
19th Dec 20257:30 amRNSCancellation of Treasury Shares
19th Dec 20257:30 amRNSCancellation of Treasury Shares
17th Dec 20257:01 amRNSCFO Retirement
17th Dec 20257:00 amRNSSerco pre-close trading update
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20254:30 pmRNSBlock listing Interim Review
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSSerco awarded UK prison contract
28th Nov 20256:20 pmRNSTransactions in own shares and Total Voting Rights
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.